Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of nangibotide in mechanically ventilated patients with COVID-19 and systemic inflammation
2020-001504-42Phase 2Terminated
- Sponsor
- Inotrem
- Start
- Apr 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Nangibotide with Placebo (2 arms). Primary endpoint: Incidence of adverse events and mortality until day 28. Started Apr 2020; status: terminated.
02
Drugs
nangibotide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001504-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001504-42.